-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EvkDCThC5N691mDqRIEkGZSUoP/PtIN6c+CbjfLjvgTIoPMMTSVQqveV2oftK3y+ ILhjmrXLpHDaHkDZ4ywLXw== 0001072613-08-001763.txt : 20080909 0001072613-08-001763.hdr.sgml : 20080909 20080909171750 ACCESSION NUMBER: 0001072613-08-001763 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080828 ITEM INFORMATION: Other Events FILED AS OF DATE: 20080909 DATE AS OF CHANGE: 20080909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001265449 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50960 FILM NUMBER: 081063499 BUSINESS ADDRESS: STREET 1: 310 AUTHORITY DRIVE CITY: FITCHBURG STATE: MA ZIP: 01420 BUSINESS PHONE: 6176292415 MAIL ADDRESS: STREET 1: 310 AUTHORITY DRIVE CITY: FITCHBURG STATE: MA ZIP: 01420 8-K 1 form8-k_16098.htm FORM 8-K DATED AUGUST 28, 2008 Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934


DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED)

August 28, 2008


INTEGRATED PHARMACEUTICALS, INC
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


COMMISSION FILE NUMBER 000-50960

 
Integrated Pharmaceuticals, Inc.
(Exact name of small business issuer in its charter)
 
Idaho
04-3413196
(State or other jurisdiction of incorporation or organization) 
(I.R.S. Employer Identification No.)
   
310 Authority Drive
Fitchburg, MA 01420
(Address of principal executive offices) (Zip Code)

(978) 696-0020
(Issuer’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM  8.01.   OTHER EVENTS
 
Suspension of Business
 
On August 28, 2008, the Board met to consider a Company-wide layoff that the President executed on August 22, 2008.  Upon consideration of the problems that the Company has encountered in trying to execute on its business plan, the Board voted to suspend all activity related to bringing its water product to market, and to focus instead on reducing or eliminating its liabilities and converting the Company to an inactive shell.
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the registrant has duly caused  this  report to be signed on its behalf by the undersigned thereunto duly authorized.

 
     
  INTEGRATED PHARMACEUTICALS, INC.
 
 		  
 		  
 
DATE:  September 9, 2008 By:   /s/ Peter Featherston
 
Peter Featherston
 
President and Chief Executive Officer

-----END PRIVACY-ENHANCED MESSAGE-----